AUBASS’ AUTOSAR Adaptive Platform Solution Ported on Kalray’s Intelligent Processor
AUBASS CO., LTD. and Kalray Corporation (Paris:ALKAL) (Euronext Growth Paris — FR0010722819 — ALKAL) today announced that its AUBIST Adaptive Platform, a solution compliant with AUTOSAR Adaptive Platform specification, is now ported and supports Kalray MPPA® intelligent processor. Such complete solution has been already delivered to pre-selected major car manufacturers.
AUTOSAR (“AUTomotive Open System ARchitecture”) is a worldwide development partnership of car manufacturers, suppliers and other companies from the electronics, semiconductor and software industries to develop and introduce an open, standardized software architecture for automotive ECUs (electronic control units). The "core partners" of AUTOSAR are the BMW Group, Bosch, Continental, Daimler AG, Ford, General Motors, PSA Group, Toyota and the Volkswagen Group. Compared to AUTOSAR Classic Platform, the Adaptive Platform is based on multi-process POSIX1 operating systems and allows the applications and features of an automotive high-performance ECU to evolve throughout the lifecycle of a vehicle, including Over-The-Air updates.
AUBIST Adaptive Platform is a software platform that is compliant to the AUTOSAR Adaptive Platform specification for the high-performance computing of in-vehicle systems. It is integrated with AUBIST OS POSIX, a POSIX-compliant Real-Time OS with unique distributed microkernel design that fully supports Kalray MPPA® Manycore architecture, enabling Adaptive Applications to seamlessly utilize the Manycore parallel processing computing power.
AUBIST AP's support for Kalray MPPA Coolidge makes it one of the best platforms for high-performance computing of automotive systems such as ADAS and autonomous driving, which require real-time processing of a huge sensor data, image/voice processing, and encryption/signal processing.
“AUBIST Adaptive Platform maximizes Kalray’s MPPA® processor performance and enables integrated power efficient system development., We are very excited to expand the use of Kalray’s MPPA intelligent processor for AUTOSAR compliant platforms,” said Stéphane Cordova, Vice-President of Embedded Business Unit at Kalray.
“AUBIST Adaptive Platform's support for Kalray's MPPA® enhanced the lineup of high-performance automotive platforms for ADAS (Advanced Driver-Assistance Systems) and autonomous driving. Kalray has unique technology to achieve extremely high computing performance and energy efficiency. In contrast to server processors, Kalray’s MPPA® can be utilized in real-time systems. The combination of Kalray's processor and our AUBIST Adaptive Platform allows system development with high computing capability and real-time performance, providing platforms for the next-generation of intelligent in-vehicle systems,” said Hasegawa Katsutoshi, Director of, AUBASS CO., LTD.
Company and product names in this document are trademarks or registered trademarks of their respective companies.
ABOUT AUBASS CO., LTD.
AUBASS helps to enhance efficiency and quality across all areas of automotive electronics system development, providing basic software basing on global AUTOSAR with reliable technology and supporting automotive electronics technology for the world and for the future. Through the supply of safe and easy-to-use platform software, AUBASS is contributing to the rapidly evolving automotive society, which includes advanced autonomous driving and the connected car. AUBASS web site: https://www.aubass.co.jp/
Kalray (Euronext Growth Paris — FR0010722819 — ALKAL) is the pioneer in processors for new intelligent systems. As a real technological breakthrough, “intelligent” processors have the capability to analyze on the fly, and in an intelligent manner, a very large amount of information, and to make decisions and interact in real time with the outside world. These intelligent processors will be deployed extensively in fast-growing sectors, such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as healthcare equipment, drones, and robots. Kalray’s offering encompasses both processors and complete solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l'énergie atomique et aux énergies alternatives”, the French Alternative Energies and Atomic Energy Commission), Kalray serves customers such as server manufacturers, intelligent system integrators, and consumer product manufacturers, including car makers. For more information, visit www.kalrayinc.com.
1SIX: The Portable Operating System Interface is a family of standards specified by the IEEE Computer Society for maintaining compatibility between operating systems.
CONTACTS FOR INVESTORS
+33 4 76 18 90 71
ACTUS finance & communication
+ 33 1 53 67 36 79
+33 4 76 18 90 71
ACTUS finance & communication
+ 33 4 72 18 04 92
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)20.9.2019 16:30:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents results from the matching-adjusted indirect comparison (MAIC) of cabozantinib (Cabometyx®) versus regorafenib (Stivarga®) for the second-line treatment (2L) of patients with advanced hepatocellular carcinoma (aHCC) who received sorafenib as the only prior systemic therapy. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that cabozantinib offers greater efficacy versus regorafenib. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that in the 2L CELESTIAL sub-population who had received sorafenib as the only prior systemic therapy, cabozantinib significantly improved progression-free survival (PFS), with an additional 2.4 months provided vs. regorafenib (5.6 months vs. 3.2 months [95% confidence interval (CI): 4.90-7.26], p<0.05). Median overall survival (OS) was also favorable with cabozantinib (11.4 months vs. 10.8 months), though statistical significance was not met
RoboSense RS-LiDAR-M1 Smart LiDAR Sensor Wins AutoSens Awards 201920.9.2019 13:30:00 CEST | Press release
On September 18, 2019, RoboSense announced at Brussels, Belgium that its flagship product RS-LiDAR-M1 Smart LiDAR Sensor has been awarded the elite AutoSens Awards trophy in the “Best Automotive Safety System” category, given to only the highest-rated innovative product or technology in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005309/en/ Robosense Along With Other Winnners At The Autosens Awards Ceremony At Brussels, Belgium (Photo: Business Wire) True autonomous driving requires human-like advanced sensing of the environment for driving with little or no human input. The safety of passengers and passers-by is always the priority concern for autonomous driving. When the RS-LiDAR-M1 is integrated into the current autonomous driving car perception system, it overcomes the weaknesses of millimeter wave radar and camera technologies on identifying obstacles, and eliminates car accidents, such
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases20.9.2019 12:00:00 CEST | Press release
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases. In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past
Visa B2B Connect Expands to 32 New Countries and Announces Integration With Infosys20.9.2019 11:00:00 CEST | Press release
Visa Inc. (NYSE:V) today announced that its Visa B2B Connect network has doubled its reach – from 30 global trade corridors at launch in June 2019, to 62, with the goal to expand to over 100 countries in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005082/en/ Visa B2B Connect (Graphic: Business Wire) In addition, Infosys, a global leader in next-generation digital services and consulting, is integrating with the Visa B2B Connect network to bring Visa B2B Connect platform access to their participating financial institutions worldwide. Through this new connection, participating financial institutions worldwide can take advantage of the ability to quickly and securely process corporate cross-border payments globally through Visa B2B Connect.1 “Visa B2B Connect is a fast, secure and more efficient network, designed specifically to overcome obstacles in the cross-border corporate payments space,” said Alan Koenigsbe
Open Day at ISAE-SUPAERO!20.9.2019 09:53:00 CEST | Press release
As part of the Science Festival, this year organized on the theme of “Talking about Science, Imagining the Future”, ISAE-SUPAERO will open up its entire campus to the public on Saturday, October 12th from 10 am to 6 pm. Intended for families, companies, partners, journalists and alumni, this event should bring in over 3,000 attendees, as was the case in the three previous years! The program for the day includes many opportunities to discover science today and our vision of the science of the future, with the challenges this entails for the future of our planet. On the program: ➢ Visits to the laboratories and research departments with flight simulators ➢ Visit to the aeroacoustic wind tunnel, unique in Europe, ➢ Demonstrations: how to fly an airplane, Enoskelet, augmented humans, aeroelasticity, drones, use of the gyroscopic effect in space systems, piezoelectric effect, lasers for communicating at the speed of light on Earth and in space, the infinitely small in 3D, Robot Firefighter
William Priest to Step Down as CEO in 2020, Will Remain at Firm as Executive Chairman and Co-CIO20.9.2019 07:00:00 CEST | Press release
Epoch Investment Partners, Inc., announced that William Priest will step down as the firm's CEO effective April 1, 2020. He will become Epoch's Executive Chairman and will continue to lead the investment team and serve as co-CIO. He will also retain his portfolio management responsibilities, including his lead portfolio manager role with Epoch's Global Choice and Global Absolute Return strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005076/en/ Philipp Hensler (Photo: Business Wire) Philipp Hensler, Epoch's President and COO, will become the firm's CEO. Hensler brings to the role extensive leadership experience at asset management firms globally. His earlier background as a portfolio manager has imbued him with an investment-oriented perspective that aligns with Epoch's investment-centric culture. “Investing remains my lifelong passion," said Priest, who helped found Epoch in 2004. “Best practice suggests a s